Skip to main content
SpringerLink
Log in

Oncogenes, Tumour Markers and Monoclonal Antibodies

  • Conference paper
The Medical Management of Prostate Cancer

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

  • 35 Accesses

Abstract

Rapid progress in molecular biology and in genetic engineering in recent years has enabled the detection of changes in the genome of normal cells responsible for changes in the cell functions which may contribute to the development of cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anderson JR: Tumours:II. The aetiology of cancer. In: Muir’s Textbook of Pathology. Edward Arnold, London. 1985, p 13.1

    Google Scholar 

  2. Horan Hand P, Thor A, Wunderlich D, Muraro R, Caruso A and Schlom J: Monoclonal antibodies of predefined specificity detect ras gene expression in human mammary and colon carcinomas. Proc Natl Acad Sci 1984 (81):5227

    Article  PubMed  CAS  Google Scholar 

  3. Hunter T and Sefton BM: The transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc Natl Acad Sci 1980 (77): 1311

    Google Scholar 

  4. Kirschenbaum A and Droller MJ: Update on oncogenes and relevance in urology. Urology 1987 (29):121

    Article  PubMed  CAS  Google Scholar 

  5. Doolittle RF: Simian sarcoma virus oncogene, v-sis, is derived from the gene (or genes) encoding a platelet- derived growth factor. Science 1983 (221):275

    Article  PubMed  CAS  Google Scholar 

  6. Downward J: Close similarity of epidermal growth factor receptor and V-erb - B oncogene protein sequences. Nature 1984 (307):521

    Article  PubMed  CAS  Google Scholar 

  7. Pacadas LF, Tabin CJ, Shih C and Weinberg RA: Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 1982 (297):474

    Article  Google Scholar 

  8. Peehl DM and Stamey TA: Oncogenes; a review with relevance to cancers of the urogenital tract. J Urol 1986 (135):897

    PubMed  CAS  Google Scholar 

  9. Viola MV, Fronowitz F, Oravez S, Deb S, Finkel G, Lundy J, Hand P, Thor A and Schlom J: Expression of ras Oncogene p 21 in prostate cancer. N Engl J Med 1986 (314):133

    Article  PubMed  CAS  Google Scholar 

  10. Woodard QH: Quantitative studies of beta-glycerophosphatase activity in normal and neoplastic tissues. Cancer 1956 (9):352

    Article  PubMed  CAS  Google Scholar 

  11. Li HC, Chernoff J and Kirschenbaum MA: A phosphotyrosinylprotein phosphatase activity associated with acid phosphatase from human prostate gland. Eur J Biochem 1984 (138):45

    Article  PubMed  CAS  Google Scholar 

  12. Rijnders AWM, van der Korput JAGM, van Steenbrugge GJ, Romijn JC and Trapman J: Expression of cellular oncogenes in human prostatic carcinoma cell lines. Biochem Biophys Res Commun 1985 (132):548

    Article  PubMed  CAS  Google Scholar 

  13. McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS and Stamey TA: Patterns of progression in prostate cancer. Lancet 1986 (l):60

    Article  Google Scholar 

  14. Isaacs JT: Pre-malignant changes in the prostate - an animal model. Prostate 1985 (7):228

    Google Scholar 

  15. Gutman EB, Sproul EE, Gutman AB: Significance of increased phosphatase activity at the site of osteoplastic metastases secondary to carcinoma of the prostate gland. Am J Cancer 1936 (28):485

    CAS  Google Scholar 

  16. Vihko P, Lukkarinen O, Kontturi M, Vihko R: Effectiveness of radioimmunoassay of human prostate-specific acid phosphatase in the diagnosis and follow-up of therapy in prostatic carcinoma. Cancer Res 1981 (41):1180

    PubMed  CAS  Google Scholar 

  17. Lewenhaupt A, Ekman P, Eneroth P, Eriksson A and Nordström L: Serum levels of prostatic acid phosphatase (PAP), tissue polypeptide antigen (TPA), CA-50, neopterin, and of osteocalcin in patients with prostatic carcinoma. Scand J Clin Lab Invest 1985 (45 Suppl 179):75

    Google Scholar 

  18. Gittes RF: Serum acid phosphatase and screening for carcinoma of the prostate. Editorial retrospective. N Engl J Med 1983 (309):852

    Article  PubMed  CAS  Google Scholar 

  19. Scardino PT, Seale C, Carlton EC: The prognostic significance of enzymatic prostatic acid phosphatase in clinically localized prostatic cancer. J Urol 1984 (131, part 2) Abstract 220, p 158A

    Google Scholar 

  20. Lewenhaupt A, Ekman P, Eneroth P, Nilsson B and Nordström L: Tissue polypeptide antigen (TPA) as a prognostic aid in human prostatic carcinoma. The Prostate 1985 (6):185

    Article  Google Scholar 

  21. Nordström L, Ekman P, Eneroth P and Lewenhaupt A: Isoenzyme pattern of prostatic acid phosphatase in serum, urine, and homogenates from men and women. Scand J Clin Lab Invest 1985 (45 Suppl 179):89

    Google Scholar 

  22. Wang MC, Loor RM, Li SL and Chu TM: Physico-chemical characterization of prostate antigen purified from human prostate gland and seminal plasma. IRCS Med Sci 1983 (11):327

    CAS  Google Scholar 

  23. Killian CS, Lang N, Emrich LJ, Vargas FP, Kuriyama M, Wang MC, Slack NH, Papsidero LD, Murphy GP and Chu TM: Prognostic importance of Prostate Specific Antigen for monitoring patients with stages B2 to D1 prostate cancer. Cancer Res 1985 (45):886

    PubMed  CAS  Google Scholar 

  24. Killian CS, Emrich LJ, Vargas FP, Yang N, Wang MC, Priore RL, Murphy GP and Chu TM: Relative reliability of five serially measured markers for prognosis of progression in prostate cancer. JNCI 1986 (76):179

    PubMed  CAS  Google Scholar 

  25. Lewenhaupt A, Ekman P, Eneroth P and Nilsson B: Reliability of PAP, PSA, TPA, Neopterin, Osteocalcin, CA-50, TK, CRN, tumour grade and stage in predicting prognosis in human prostate cancer (submitted)

    Google Scholar 

  26. Siddall JK, Shetty SD and Cooper EH: Measurements of serum gamma-seminoprotein and prostate specific antigen evaluated for monitoring carcinoma of the prostate. Clin Chem 1986 (32):2040

    PubMed  CAS  Google Scholar 

  27. Huber C, Fuchs D, Hausen A, Margreiter R, Reibnegger G, Spielberger M and Wächter H: Pteridines as a new marker to detect human T cells activated by allogenic or modified self major histocompatibility complex (MHC) determinants. J Immun 1983 (130):1047

    PubMed  CAS  Google Scholar 

  28. Margreiter R, Fuchs D, Hausen A, Huber C, Reibnegger G, Spielberger M and Wächter H: Neopterin as a new biochemical marker for early diagnosis of renal allograft rejection: experience based upon evaluation of 100 consecutive cases. Transplantation 1983 (36):650

    Article  PubMed  CAS  Google Scholar 

  29. Goebel FD, Erfle V, Piechowiak H, Hien P, Schloz H and Hehlman R: The relations of HTLV-III antibodies to neopterin and beta-2-microglobulin in the serum of patients with AIDS or persons at risk. ln:Biochemical and Clinical Aspects of Pteridines, Vol 4. De Gruyter, Berlin 1985 p 319

    Google Scholar 

  30. Lewenhaupt A, Ekman P, Eneroth P, Eriksson A and Nordström L: Neopterin as a prognostic aid in prostatic carcinoma. Eur J Urol 1986 (12):422

    CAS  Google Scholar 

  31. Deftos J, Parthermore G & Price A: Changes in plasma bone Gla-protein during treatment of bone disease. Calif Tissue Int 34:121, 1982.

    Article  CAS  Google Scholar 

  32. Lewenhaupt A, Ekman P, Eneroth P, Kallner A and Nordström L: Tumour Markers in Human Prostatic Carcinoma. On optimation of reference values, (in press).

    Google Scholar 

  33. Lüning B and Nilsson U: Sequence homology between TPA and intermediate filament proteins. Acta Chem Scand 1983 (37 B):731

    Article  Google Scholar 

  34. Skryten A, Unsgaard B, Björklund B and Englund G: Serum TPA related to activity in a wide spectrum of cancer conditions. Tumor Diagn 1981 (3):117

    Google Scholar 

  35. Gronowitz JS, Källander CFR, Diderholm H, Hagberg H and Pettersson V: Application of an in vitro assay for serum Thymidine Kinase: Results on viral disease and malignancies in humans. Int J Cancer 1984 (33):5

    Article  PubMed  CAS  Google Scholar 

  36. Stein BS, Petersen RO, Vangore S and Kendall AR: Immunoperoxidase localization of prostate specific antigen. Am J Surg Pathol 1985 (6):553

    Article  Google Scholar 

  37. Lewenhaupt A, Collins P and Ekman P: Immunohistochemical localisation of prostatic acid phosphatase, prostate specific antigen, and of tissue polypeptide antigen in human prostatic carcinoma (submitted)

    Google Scholar 

  38. Ehrlich P: Collected Studies on Immunity. John Wiley, New York 1906

    Google Scholar 

  39. Deguchi T, Chu TM, Leong S, Horoszewicz JS and Lee C: Effect of methotrexate-monoclonal anti-prostatic acid phosphatase antibody conjugate on human prostate tumour. Cancer Res 1986 (46):3751

    PubMed  CAS  Google Scholar 

  40. Webb K, Ware J and Paulson DF: A review: prostate monoclonal antibodies - the magic bullet. Urology 1986 (4): 193

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Karolinska Hospital, Stockholm, Sweden

    Lennart Andersson

Authors
  1. Lennart Andersson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Algemeen Ziekenhuis Middelheim, Lindendreef 1, B-2020, Antwerpen, Belgïe

    Louis Denis

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Andersson, L. (1988). Oncogenes, Tumour Markers and Monoclonal Antibodies. In: Denis, L. (eds) The Medical Management of Prostate Cancer. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73238-6_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-73238-6_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-73240-9

  • Online ISBN: 978-3-642-73238-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation